UCB brings Cradle's AI protein design platform into its antibody discovery projects

UCB, the Brussels-based biopharmaceutical group, said on 4 November 2026 that it has signed a strategic collaboration with Cradle, the Amsterdam company behind an AI platform for protein design and engineering, to bring that platform into its antibody discovery work¹. Neither company disclosed financial terms¹.

What the deal covers

UCB will use Cradle's software inside selected discovery projects, from hit generation through lead optimisation to preclinical readiness¹. The announcement does not say how many projects are involved or which diseases they target. It places the deal inside UCB's wider digital antibody discovery and engineering programme, which combines the company's in-house antibody discovery platform with computational science, disease biology and a network of outside technology and research partners¹.

The working method is a feedback loop. As UCB scientists run programmes on the platform, their experimental results are fed back into models built for each programme, which the companies describe as a compounding learning loop¹. The aim is to optimise candidates across the full set of properties a drug needs, rather than one property at a time, and to move faster towards a candidate¹.

Alistair Henry, UCB's chief scientific officer, said the company sees AI "not as something to chase for its own sake, but as a scientific force multiplier that augments human expertise across biology, chemistry, and translational research"¹. He added that predictive modelling paired with wet-lab validation could let UCB "design better molecules, learn faster"¹. Stef van Grieken, Cradle's chief executive and co-founder, said AI would matter most in biologics R&D once it is scaled beyond single experiments or programmes and becomes part of how a whole discovery organisation works¹.

What it means for the market

For UCB, the deal adds an outside engineering platform to a discovery engine that serves a business with more than 9,000 staff in about 40 countries and revenue of €7.7 billion in 2025¹. The company focuses on severe diseases of the immune system and central nervous system, so antibodies designed through the collaboration would be expected to sit in those areas, though the release names no programmes¹.

For Cradle, the agreement extends a commercial base it already describes as spanning more than 80 active R&D programmes across pharmaceuticals, industrial biotechnology, agriculture and consumer goods¹. The company is backed by IVP, Index Ventures and Kindred Capital¹. The release frames the UCB deal as bringing Cradle across UCB's biotherapeutics pipeline, which points to a software model sold as a shared platform for many programmes and modalities rather than as a per-molecule service, with UCB's own scientists running it and UCB's own lab data feeding the models¹.

Caveats

This is a company announcement with no financial terms, no named targets and no timeline for candidates¹. UCB's own forward-looking statements warn that preclinical results do not guarantee safety and efficacy in humans, and that computer models cannot yet reproduce the complexity of the human body¹. Whether the platform shortens UCB's path to a development candidate will only become visible when the company reports programmes that came through it.